Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.com
StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research report report published on Sunday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Several other research analysts have also weighed in on the company. HC Wainwright reissued a “neutral” rating and set a $6.60 price target on […]
More Stories
StockNews.com Upgrades Crown Castle (NYSE:CCI) to “Hold”
Crown Castle (NYSE:CCI – Get Free Report) was upgraded by stock analysts at StockNews.com from a “sell” rating to a...
StockNews.com Begins Coverage on Dun & Bradstreet (NYSE:DNB)
Analysts at StockNews.com initiated coverage on shares of Dun & Bradstreet (NYSE:DNB – Get Free Report) in a note issued...
T2 Biosystems (NASDAQ:TTOO) Now Covered by Analysts at StockNews.com
Analysts at StockNews.com assumed coverage on shares of T2 Biosystems (NASDAQ:TTOO – Get Free Report) in a research note issued...
Thomson Reuters (NYSE:TRI) Upgraded to “Hold” at StockNews.com
Thomson Reuters (NYSE:TRI – Get Free Report) (TSE:TRI) was upgraded by analysts at StockNews.com from a “sell” rating to a...
Visionary (NYSE:GV) Upgraded to Sell at StockNews.com
Visionary (NYSE:GV – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research...
B. Riley Issues Positive Outlook for Teck Resources Earnings
Teck Resources Ltd. (TSE:TCK – Free Report) – Investment analysts at B. Riley lifted their Q2 2025 earnings per share...